SCHEMBL30984010

SCHEMBL30984010

CC(C)(C)OC(=O)N1CCN(CCOc2ccc(-c3nc4c(OC(C)(C)C(F)(F)F)ncnc4n3Cc3ccccc3)c(Cl)c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 2/20 0.43
▸ CNR2 P34972 2/20 0.43
▸ GPR4 P46093 1/20 0.41
▸ BRD4 O60885 3/20 0.39
▸ DRD3 P35462 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SQOR Q9Y6N5 1/20 0.38
▸ PIK3CD O00329 5/20 0.38
▸ ADORA2A P29274 1/20 0.37
▸ KIT P10721 1/20 0.37
▸ FLT3 P36888 1/20 0.37
▸ MAOA P21397 1/20 0.37
▸ MAOB P27338 1/20 0.37
▸ EPHX2 P34913 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983846 0.90 CNR1 (0.47) CNR1CNR2GPR4BRD4DRD3
SCHEMBL30983802 0.89 CNR1 (0.43) CNR1CNR2GPR4BRD4DRD3
SCHEMBL30984074 0.88 CNR1 (0.42) CNR1CNR2GPR4BRD4DRD3
SCHEMBL30984027 0.88 CNR1 (0.42) CNR1CNR2GPR4BRD4DRD3
SCHEMBL30983857 0.87 PDE2A (0.44) KDM4EALDH1A1LMNAGAAHTT
SCHEMBL30983785 0.86 CNR1 (0.41) CNR1CNR2GPR4BRD4DRD3
SCHEMBL30984030 0.86 PIK3CD (0.45) CNR1CNR2PIK3CDADORA2A
SCHEMBL30983947 0.86 ADORA2A (0.45) CNR1CNR2GPR4DRD3LMNA
SCHEMBL30983893 0.85 CNR1 (0.42) CNR1CNR2GPR4KDM4EALDH1A1
SCHEMBL30983888 0.85 CNR1 (0.40) CNR1CNR2GPR4BRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed
Send feedback